Wiki source
NAD+ Metabolism and Boosters
A read-only view of this entry as wiki markup. This atlas is curated, so editing is disabled — but the source shows exactly how the page is structured.
# NAD+ Metabolism and Boosters Portal: Longevity Science Stage: Early human, mixed results Evidence: Early human Template: Intervention Risk: Low Reversibility: Reversible Last reviewed: May 2026 == Summary == NAD+ declines with age and is central to energy metabolism and repair, but whether raising it with precursors produces meaningful healthspan benefit in humans remains unsettled. == Key takeaways == * NAD+ is a coenzyme essential to metabolism and to repair enzymes such as sirtuins and PARPs. * Precursors like NR and NMN reliably raise blood NAD+ markers, but clinical outcomes are inconsistent. * Tissue-level effects and long-term safety are the unresolved questions, not whether levels can be raised. == Mechanism == NAD+ carries electrons in metabolism and is consumed by enzymes that repair DNA and regulate stress responses. Levels fall with age in many tissues, which motivated the idea that restoring NAD+ could restore function. Supplemental precursors — nicotinamide riboside and nicotinamide mononucleotide — are converted to NAD+ and consistently raise measurable NAD+ metabolites in blood. == What the trials show == Human trials generally confirm that precursors raise NAD+ markers and are well tolerated over the periods studied. Functional benefits — on strength, metabolism, or cardiovascular measures — have been small or inconsistent across studies. A raised blood marker does not guarantee the relevant tissues benefit, and some biology suggests context matters, including concerns about fueling existing disease. The honest current status is a plausible target with unproven clinical payoff. == Open questions == * Do raised blood NAD+ levels translate to the tissues that matter? * Are there populations where boosting NAD+ is harmful rather than neutral? == Watchlist == * Tissue-specific NAD+ measurement * Adequately powered outcome trials * Long-term safety == References == * Chronic nicotinamide riboside supplementation trial — Martens et al., Nature Communications, 2018. https://pubmed.ncbi.nlm.nih.gov/29599478/. Showed NR raises NAD+ and is well tolerated, with modest physiological effects. * NAD+ metabolism review — Covarrubias et al., Nature Reviews Molecular Cell Biology, 2021. https://pubmed.ncbi.nlm.nih.gov/33353981/. Reviews NAD+ decline in aging and the state of precursor evidence. == Categories == [[Category:Longevity Science]] [[Category:NAD+]] [[Category:metabolism]] [[Category:supplements]]